Share-based Payment Arrangement, Expense of Keros Therapeutics, Inc. from 31 Mar 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Keros Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2019 to 31 Dec 2025.
  • Keros Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $7,305,000, a 21% decline year-over-year.
  • Keros Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $28,696,000, a 18% decline year-over-year.
  • Keros Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $28,696,000, a 18% decline from 2024.
  • Keros Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $34,872,000, a 21% increase from 2023.
  • Keros Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $28,763,000, a 54% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Keros Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $28,696,000 $7,305,000 -$1,895,000 -21% 01 Oct 2025 31 Dec 2025 10-K 04 Mar 2026 2025 FY
Q3 2025 $30,591,000 $3,986,000 -$4,831,000 -55% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $35,422,000 $8,542,000 -$243,000 -2.8% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $35,665,000 $8,863,000 +$793,000 +9.8% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $34,872,000 $9,200,000 +$1,876,000 +26% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2026 2025 FY
Q3 2024 $32,996,000 $8,817,000 +$106,000 +1.2% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $32,890,000 $8,785,000 +$1,744,000 +25% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $31,146,000 $8,070,000 +$2,383,000 +42% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $28,763,000 $7,324,000 +$2,578,000 +54% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $26,185,000 $8,711,000 +$3,957,000 +83% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $22,228,000 $7,041,000 +$2,247,000 +47% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $19,981,000 $5,687,000 +$1,299,000 +30% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $18,682,000 $4,746,000 +$1,451,000 +44% 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
Q3 2022 $17,231,000 $4,754,000 +$1,670,000 +54% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $15,561,000 $4,794,000 +$1,945,000 +68% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $13,616,000 $4,388,000 +$1,894,000 +76% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $11,722,000 $3,295,000 +$1,773,000 +116% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 $9,949,000 $3,084,000 +$1,660,000 +117% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $8,289,000 $2,849,000 +$1,710,000 +150% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $6,579,000 $2,494,000 +$2,482,000 +20683% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2021 Q1
Q4 2020 $4,097,000 $1,522,000 +$1,504,000 +8356% 01 Oct 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
Q3 2020 $2,593,000 $1,424,000 +$1,407,000 +8276% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $1,186,000 $1,139,000 +$1,126,000 +8662% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $60,000 $12,000 +$1,000 +9.1% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $59,000 $18,000 01 Oct 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
Q3 2019 $17,000 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $13,000 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $11,000 01 Jan 2019 31 Mar 2019 10-Q 22 May 2020 2020 Q1

Keros Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $28,696,000 -$6,176,000 -18% 01 Jan 2025 31 Dec 2025 10-K 04 Mar 2026 2025 FY
2024 $34,872,000 +$6,109,000 +21% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2026 2025 FY
2023 $28,763,000 +$10,081,000 +54% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
2022 $18,682,000 +$6,960,000 +59% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
2021 $11,722,000 +$7,625,000 +186% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $4,097,000 +$4,038,000 +6844% 01 Jan 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
2019 $59,000 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.